• Le 21 June 2022

    Mardi 21 Juin 2022 à 11H,

    Amphi Denis Escande, IRS-UN

    false false
  • Mardi 21 Juin 2022 à 11H,

    Amphi Denis Escande, IRS-UN

Pr Guy GOROCHOV, Sorbonne Université/ Inserm U1135 Mardi 21 Juin 2022 à 11H, Amphi Denis Escande, IRS-UN

“Deleterious and beneficial antibodies in COVID-19”

Invité par le Dr Dorian McIlroy

Guy Gorochov first trained as a clinician in Paris, then as a post-doctoral fellow, first at the Weizmann Institute (Israel) working on the first generation of Chimeric Antigen Receptors (CARs) and then at the MRC laboratory of Molecular Biology in Cambridge (U.K.), working on antibody engineering. He then joined the Department of Immunology of Hospital Pitié-Salpêtrière & Sorbonne Université in 1994 and become head of immunology department in 2017. The team developed a platform dedicated to study the interface between IgA and microbes (1), including SARS-CoV-2 (2).

Our recent observation that distinct cytokine profiles are associated with COVID-19 severity and mortality (3) implies the need for a personalized precision medicine approach to successfully treat COVID-19 patients (4). The team is currently involved in the characterization of anti-type I Interferon antibodies associated with severe COVID-19 we contributed to describe (5) and of their impact on the evolution of autoimmunity (submitted).

  1. Fadlallah, Sci Transl Med. 2018. 10.1126/scitranslmed.aan1217
  2. Sterlin, Sci Transl Med. 2021. 10.1126/scitranslmed.abd2223
  3. Dorgham, J Allergy and Clin Immunol. 2021. 10.1016/j.jaci.2021.03.047
  4. Neumann, Lancet 2021. 10.1016/S0140-6736(21)01427-6
  5. Bastard, Science. 2020. 10.1126/science.abd4585